Guardant Health, Inc.

Guardant Health is a precision oncology company specializing in blood-based liquid biopsy testing for cancer detection, staging, and treatment monitoring. The company develops and commercializes circulating tumor DNA (ctDNA) tests that enable early cancer screening and inform treatment decisions across all stages of disease. Their primary product lines include Shield (cancer screening via blood test), Guardant Complete (advanced cancer oncology testing), and BioPharma Solutions for drug development and clinical trials. With over 500,000 tests performed and 12,000 physicians utilizing their platform, Guardant Health provides data-driven insights to improve clinical outcomes through biomarker analysis and minimal residual disease (MRD) detection. The company operates a CLIA-certified laboratory in the Bay Area and maintains regulatory compliance for commercialized diagnostics. Their technology supports personalized cancer care by identifying genetic mutations, tumor characteristics, and treatment response markers from blood samples, reducing reliance on invasive tissue biopsies and enabling earlier intervention.